12.87

0.23% -0.03

After Hours: 12.14 -0.73 -5.67%

Schrodinger Inc (SDGR)

Overview News Price History Option Chain Financials Why SDGR Down? Discussions Forecast

Schrodinger Inc stock is traded at $12.87, with a volume of 1.51M. It is down -0.23% in the last 24 hours and up +11.14% over the past month. Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Previous Close:

$12.90

Open:

$12.78

24h Volume:

1.51M

Relative Volume:

1.04

Market Cap:

$961.66M

Revenue:

$255.87M

Net Income/Loss:

$-103.27M

P/E Ratio:

-9.1218

EPS:

-1.4109

Net Cash Flow:

$12.46M

1W Performance:

+5.15%

1M Performance:

+11.14%

6M Performance:

-34.90%

1Y Performance:

-50.46%

1-Day Range:

$12.54

$13.02

1-Week Range:

$11.59

$13.25

52-Week Range:

$10.95

$27.63

Schrodinger Inc Stock (SDGR) Company Profile

Name

Schrodinger Inc

Sector

Healthcare (1106)

Industry

Health Information Services (50)

Phone

503-299-1150

Address

1540 BROADWAY, NEW YORK, NY

Employee

850

Twitter

@schrodinger

Next Earnings Date

2026-05-05

Latest SEC Filings

SDGR's Discussions on Twitter

Compare SDGR vs VEEV, BTSG, TEM, HQY, DOCS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SDGR Schrodinger Inc	12.87	963.90M	255.87M	-103.27M	12.46M	-1.4109
VEEV Veeva Systems Inc	171.19	27.80B	3.20B	908.91M	1.39B	5.4168
BTSG Brightspring Health Services Inc	51.44	10.38B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	54.07	10.01B	1.27B	-245.03M	-245.36M	-1.4071
HQY Healthequity Inc	82.63	6.94B	1.31B	215.20M	408.32M	2.4627
DOCS Doximity Inc	25.77	4.60B	637.78M	239.40M	307.21M	1.1909

Schrodinger Inc Stock (SDGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Sep-30-25	Initiated	Goldman	Neutral
Aug-15-25	Downgrade	Citigroup	Buy → Neutral
Aug-14-25	Initiated	Barclays	Overweight
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight
Jul-02-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
May-05-23	Resumed	Piper Sandler	Overweight
Dec-19-22	Initiated	Goldman	Neutral
Mar-01-22	Initiated	Citigroup	Buy
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-11-21	Downgrade	BofA Securities	Buy → Neutral
Oct-13-21	Initiated	Berenberg	Buy
Sep-01-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
May-25-21	Initiated	Craig Hallum	Buy
Nov-23-20	Upgrade	BofA Securities	Neutral → Buy
Oct-12-20	Upgrade	Jefferies	Hold → Buy
Mar-02-20	Initiated	BMO Capital Markets	Outperform
Mar-02-20	Initiated	Jefferies	Hold
Mar-02-20	Initiated	Morgan Stanley	Equal-Weight

View All

Schrodinger Inc Stock (SDGR) Latest News

08:51 AM

Schrödinger outlines $218M-$228M 2026 ACV outlook with focus on hosted transition and Bunsen early access release - MSN

08:51 AM

08:41 AM

Schrödinger Earnings Call: Growth Now, Profits Later - TipRanks

08:41 AM

07:24 AM

Schrödinger Inc (NASDAQ:SDGR) Q1 2026 Earnings: Revenue Beat Fails to Offset Loss Miss, Stock Slides - ChartMill

07:24 AM

06:03 AM

Schrödinger Q1 2026 slides: AI platform advances amid transition - Investing.com

06:03 AM

05:28 AM

Earnings call transcript: Schrödinger misses EPS but beats revenue in Q1 2026 - Investing.com

05:28 AM

04:51 AM

Earnings Flash (SDGR) Schrodinger, Inc. Reports Q1 Revenue $58.6M, vs. FactSet Est of $47.6M - marketscreener.com

04:51 AM

04:30 AM

Schrödinger (SDGR) Q1 2026 Earnings Transcript - The Globe and Mail

04:30 AM

04:18 AM

Schrödinger tees up AI drug-discovery tool as Ajax sale hits $2.3B - Stock Titan

04:18 AM

04:09 AM

Schrödinger (NASDAQ: SDGR) Q1 2026 revenue, loss and cash position - Stock Titan

04:09 AM

04:06 AM

Schrödinger (NASDAQ: SDGR) posts Q1 2026 $58.6M revenue, keeps outlook - Stock Titan

04:06 AM

04:05 AM

Schrödinger Reports First Quarter 2026 Financial Results - Yahoo Finance UK

04:05 AM

11:16 AM

Can Schrödinger’s (SDGR) AI-Hosted Push Recast Its Investment Story Beyond Drug Discovery Hype? - simplywall.st

11:16 AM

07:43 AM

Insider sales reported for SDGR (NASDAQ: SDGR) including 752/775/608 shares - Stock Titan

May 01, 2026

SDGR Stock Price, Quote & Chart | SCHRODINGER INC (NASDAQ:SDGR) - ChartMill

May 01, 2026

Apr 30, 2026

3.19M-share disclosure by Schrodinger (NASDAQ: SDGR) shows a 4.9% stake - Stock Titan

Apr 30, 2026

Apr 29, 2026

Earnings Preview: Schrodinger to Report Financial Results Post-market on May 05 - Moomoo

Apr 29, 2026

Vanguard Portfolio Management (SDGR) holds 3.91M shares, 6.04% stake - Stock Titan

Apr 29, 2026

AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance

Apr 29, 2026

Apr 28, 2026

Schrodinger (SDGR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Schrödinger Appoints Geoffrey Porges as Chief Financial Officer - Quantisnow

Apr 28, 2026

Form DEFA14A Schrodinger, Inc. - StreetInsider

Apr 28, 2026

[ARS] Schrodinger, Inc. SEC Filing - Stock Titan

Apr 28, 2026

Schrödinger (NASDAQ: SDGR) seeks approval for 3M-share equity plan increase - Stock Titan

Apr 28, 2026

Apr 27, 2026

Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.

Apr 27, 2026

Apr 26, 2026

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

Apr 26, 2026

Schrödinger updates 2025 software growth guidance to 8%-13% amid pharma scale-up delays and operational efficiency focus - MSN

Apr 26, 2026

Apr 23, 2026

Schrodinger downgraded at Citi after clinical program exit - MSN

Apr 23, 2026

Why (SDGR) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Apr 23, 2026

SDGR (Schrodinger Inc.) Q4 2025 EPS far outpaces consensus estimates, shares climb 2.32 percent.Fast Rising Picks - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026